Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 4Hypoglycemia 2Glioblastoma 2Parkinsonian Disorders 1Parathyroid Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia 1Insulinoma 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hyperinsulinism 1Hypercalcemia 1Glucose Metabolism Disorders 1Brain Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × fluorodopa F 18 × Clear all
NCT07542158 2026-04-21

Ultralow Dose PET Imaging of 18F-FDOPA

Nuclear Imaging Institute

Phase 2 Enrolling by invitation
200 enrolled
CNS

Glioma, Neoplasms, Parkinsonian Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡